---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-244019"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T12:53:25.686112+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Synlogic Q2 2021 net loss narrows to $14.5M; PKU and Enteric Hyperoxaluria trials on track for 2H readouts

## Summary
- Cash, equivalents, and investments of $115.5M as of June 30, 2021; runway into second half of 2023.
- Net loss of $14.5M ($0.28/shr) vs. $15.5M ($0.44/shr) in Q2 2020; revenue of $0.2M from Roche IBD collaboration.
- SYNB1618 Phase 2 PKU trial ongoing; Phase 1 of next-generation SYNB1934 initiated in July 2021.
- SYNB8802 Enteric Hyperoxaluria Part B enrolling; proof-of-concept data expected in 2H 2021.
- Combination arm of SYNB1891 (atezolizumab) Phase 1 in solid tumors; mature data expected by year-end.

## SEC filing metadata
- accession: 0001193125-21-244019
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000119312521244019/0001193125-21-244019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000119312521244019/d340812d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-244019
- JSON: https://secwatch.observer/filing/0001193125-21-244019.json
- Plain text: https://secwatch.observer/filing/0001193125-21-244019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.